These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Simvastatin increases circulating endothelial progenitor cells and reduces the formation and progression of diabetic retinopathy in rats.
    Author: Zhang W, Yan H.
    Journal: Exp Eye Res; 2012 Dec; 105():1-8. PubMed ID: 23059402.
    Abstract:
    Circulating endothelial progenitor cell (EPC) plays a significant role in postnatal vasculogenesis and reduction of endothelial injury. This study aimed to observe the effects of simvastatin on EPC mobilization, which could alter the rate of diabetic retinopathy (DR) formation and progression. DR was induced in male Wistar rats by S.C. administration of streptozotocin (STZ) and oral treatment with gavage of simvastatin. Circulating EPC and serum nitric oxide (NO) levels were measured by flow cytometry and the Greiss method, respectively. mRNA expression of endothelial nitric oxide synthase (eNOS), inducible nitric oxide synthase (iNOS), Angiopoietin-1 (Ang-1) and Angiopoietin-2 (Ang-2) in retinal tissue were quantified by Real-time Polymerase Chain Reaction (RT-PCR). CD31 expression, VEGF expression and retinal vascular permeability of DR were evaluated three months after STZ administration. Our results show that circulating EPCs were considerably lower in DR rats when compared to controls. Simvastatin treatment increased levels of circulating EPCs and NO. Additionally, it decreased mRNA expression levels of iNOS, Ang-1, and Ang-2, while increasing eNOS mRNA expression in retinal tissue. Retina tissue layers in simvastatin treated rats exhibited decreased edema and became organized when compared to non-simvastatin treated rats. These results suggest simvastatin increases circulating EPCs, consequently suppressing the formation and progression of DR. Our findings support that EPCs may serve as a marker for DR progression and simvastatin as a promising candidate for the clinical management of DR.
    [Abstract] [Full Text] [Related] [New Search]